GlassScriptPhysician profile
Roxana I Bodin
NPI 1215254602
$102,246.45
in general payments reported to CMS, 2019-2025
16 companies · $98K in 2025
The $98K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.53 · 2021: $43.72 · 2022: $92.39 · 2023: $108 · 2024: $4,099 · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Food and Beverage: $3,751 · Travel and Lodging: $1,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,595.50 |
| Food and Beverage | $3,750.97 |
| Travel and Lodging | $1,703.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $100,940.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $332.68 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.64 | 2019-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $134.76 | 2024-2025 | Zenpep |
| Abbvie INC. | $127.64 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.52 | 2024 | Entyvio |
| Ipsen Biopharmaceuticals, INC | $89.92 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $84.39 | 2023 | Sucraid |
| Mallinckrodt Hospital Products INC. | $61.75 | 2025 | Terlivaz |
| Novo Nordisk INC | $49.45 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $43.71 | 2022-2025 | |
| Mirum Pharmaceuticals, INC. | $42.16 | 2024-2025 | Livmarli, Chenodal, Cholbam |
| Alnylam Pharmaceuticals INC. | $29.34 | 2022 | |
| Eisai INC. | $26.02 | 2024 | |
| Mauna Kea Technologies, INC. | $22.20 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $16.53 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxana Bodin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.